C
Cadrenal Therapeutics D
D
CVKD
4.88500
USD
-0.08
(-1.51%)
Market Closed
Volume
0
EPS
-5
Div Yield
-
P/E
-1
Market Cap
12,245,801
Title: Cadrenal Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.